FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma

Abdelwahab, 2012, Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma, Ann. Oncol., 23, 10.1016/S0923-7534(20)33239-7 Aoki, 2003, Prognostic significance of dysadherin expression in advanced colorectal carcinoma, Br. J. Cancer, 88, 726, 10.1038/sj.bjc.6600778 Bai, 2020, A FXYD5/TGFbeta/SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer, Int. J. Oncol., 56, 301 Besso, 2019, FXYD5/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-beta1 and NF-kappaB pathways, Front. Oncol., 9, 1306, 10.3389/fonc.2019.01306 Chang, 2013, Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance, Cell Death Dis., 4, e875, 10.1038/cddis.2013.407 Couri, 2019, Goals and targets for personalized therapy for HCC, Hepatol Int, 13, 125, 10.1007/s12072-018-9919-1 Dimri, 2020, Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma, Cancers, 12, 10.3390/cancers12020491 2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J. Hepatol., 69, 182, 10.1016/j.jhep.2018.03.019 Fritz, 2021, Combined de-repression of chemoresistance associated mitogen-activated protein kinase 14 and activating transcription factor 2 by loss of microRNA-622 in hepatocellular carcinoma, Cancers, 13, 10.3390/cancers13051183 Jiang, 2015, Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells, Mol. Med. Rep., 12, 7239, 10.3892/mmr.2015.4363 Juurikka, 2021, MMP8 increases tongue carcinoma cell-cell adhesion and diminishes migration via cleavage of anti-adhesive FXYD5, Oncogenesis, 10, 44, 10.1038/s41389-021-00334-x Kim, 2017, Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy, J. Gastrointest. Oncol., 8, 256, 10.21037/jgo.2016.09.07 Kudo, 2018, Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial, The Lancet Gastroenterology & Hepatology, 3, 424, 10.1016/S2468-1253(18)30078-5 Lee, 2012, Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation, Cancer Sci., 103, 1280, 10.1111/j.1349-7006.2012.02302.x Li, 2021, Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma, Acta Pharmacol. Sin., 42, 301, 10.1038/s41401-020-0478-3 Lu, 2018, CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma, Cell Death Dis., 9, 646, 10.1038/s41419-018-0681-z Ma, 2021, LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells, Int. J. Med. Sci., 18, 1456, 10.7150/ijms.51256 Mijatovic, 2013, Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways, Planta Med., 79, 189, 10.1055/s-0032-1328243 Sato, 2003, Dysadherin: expression and clinical significance in thyroid carcinoma, J. Clin. Endocrinol. Metab., 88, 4407, 10.1210/jc.2002-021757 Shimamura, 2003, Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression, J. Clin. Oncol., 21, 659, 10.1200/JCO.2003.06.179 Szymonowicz, 2018, New insights into protein kinase B/Akt signaling: role of localized Akt activation and compartment-specific target proteins for the cellular radiation response, Cancers, 10, 10.3390/cancers10030078 Tan, 2017, Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the PI3K/AKT/mTOR pathway, Oncol. Res., 25, 1543, 10.3727/096504017X14886444100783 Tan, 2014, Mechanism of bFGF-binding peptide reversing adriamycin resistance in human gastric cancer cells, Int. J. Pept. Res. Therapeut., 20, 427, 10.1007/s10989-014-9402-3 Tan, 2021, Lomerizine 2HCl inhibits cell proliferation and induces protective autophagy in colorectal cancer via the PI3K/Akt/mTOR signaling pathway, MedComm, 2020, 453, 10.1002/mco2.83 Tang, 2020, The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects, Signal Transduct. Targeted Ther., 5, 87, 10.1038/s41392-020-0187-x Tummala, 2009, Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin, Cancer Chemother. Pharmacol., 64, 1187, 10.1007/s00280-009-0985-x Wei, 2019, Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC, Nat. Commun., 10, 4681, 10.1038/s41467-019-12606-7 Xu, 2018, LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85, Cancer Lett., 420, 38, 10.1016/j.canlet.2018.01.067 XueKe Liu, 2019, BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K_Akt_mTOR pathway, Am J Transl Res, 11(12), 7255 Yi, 2017, Inhibition of the AKT/mTOR pathway augments the anticancer effects of sorafenib in thyroid cancer, Cancer Biother. Radiopharm., 32, 176, 10.1089/cbr.2017.2187 Zhang, 2019, Upregulation of FoxP4 in HCC promotes migration and invasion through regulation of EMT, Oncol. Lett., 17, 3944 Zhang, 2016, NRBP2 overexpression increases the chemosensitivity of hepatocellular carcinoma cells via Akt signaling, Cancer Res., 76, 7059, 10.1158/0008-5472.CAN-16-0937 Zheng, 2019, PMPCB silencing sensitizes HCC tumor cells to sorafenib therapy, Mol. Ther., 27, 1784, 10.1016/j.ymthe.2019.06.014